Identifies themes and clusters of stock movements
Market TodayThemes and Stocks SummaryThematic Stock SearchClick here for daily refresh schedule
EARS - Auris Medical Holding Ltd
$2.64
0.00(0.00%)5:00:00 AM 1/15/2021
Auris Medical Holding Ltd., a development-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment and prevention of peripheral and central nervous disorders. The company's Phase 3 programs under the development include Keyzilen (AM-101) for the treatment of acute inner ear tinnitus; and Sonsuvi (AM-111) for the treatment of acute inner ear hearing loss. It is also developing AM-125 that is in Phase 2 clinical trial for the intranasal treatment of acute peripheral vertigo; and AM-201, which is in Phase 1b clinical trial for the prevention of weight gain and drowsiness, which are side effects of various antipsychotic drugs, as well as AM-102 for the tinnitus treatment. The company has a collaboration and license agreement with INSERM; and Xigen S.A. to develop, manufacture, and commercialize pharmaceutical products, as well as drug delivery devices and formulations for local administration of therapeutic substances to the inner ear for the treatment of ear disorders. Auris Medical Holding Ltd. was founded in 1998 and is headquartered in Hamilton, Bermuda.
Stock Chart
No summary

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Related Topics
leak data

Related Topics

Peers

Related Peers

Stock news

    12/15/2020EARS
    Auris Medical Provides Business Update

    * Net cash inflow of $13.4 million from recent registered direct offering and warrant exercises   * AM-301 program progressing towards clinical and regulatory milestones  * Strategy review ongoing Hamilton, Bermuda, December 15, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today provided a business update related to the Company’s...

    12/9/2020EARS
    Have Insiders Been Buying Auris Medical Holding Ltd. (NASDAQ:EARS) Shares?

    We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also...

    12/7/2020EARS
    Auris Medical Holding to Present at the 13th Annual LD Micro Main Event Conference

    Hamilton, Bermuda, December 7, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced that Chairman and CEO Thomas Meyer will present at the 13th Annual LD Micro Main Event investor conference on Tuesday, December 15, 2020, at 10:40 a.m. EST. The event will be webcast live and available via the event homepage https://ve.myseq...

    12/2/2020EARS
    Auris Medical Holding Ltd. Prices $8,000,000 Common Shares Offering Priced At-the-Market

    Hamilton, Bermuda, December 2, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS) (“Auris” or the “Company”), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced it has entered into securities purchase agreements with institutional investors for the purchase and sale of 2,000,000 common shares, par value CHF 0.01 per share, at an offering price of $4.00 per share, pursuant ...

    12/1/2020EARS
    Auris Medical Reports Positive In vitro Efficacy Data for AM-301 in Protecting Against Sars-CoV-2 Infection

    * Up to 99.4% reduction of viral titer in human epithelial cell culture (p<0.001) * Results suggest potential for AM-301 nasal spray to mitigate risk of Sars-CoV-2 infectionHamilton, Bermuda, December 1, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced positive efficacy data from testing AM-301 in vitro. AM-301 is a dr...

    11/20/2020EARS
    Auris Medical Launches Website for AM-301-focused Subsidiary, Altamira Medica

    Hamilton, Bermuda, November 20, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced the launch of a dedicated website for its affiliate Altamira Medica Ltd. The website, www.altamiramedica.com, offers quick and easy access to information about the Company’s development of AM-301, a drug-free nasal spray intended for self-p...

    10/15/2020EARS
    RedHill's (RDHL) RHB-204 Gets FDA Orphan Drug Designation

    RedHill (RDHL) gets Orphan Drug status from the FDA for the treatment of nontuberculous mycobacteria (NTM) disease.

    10/13/2020EARS
    Why Auris Medical's Stock Is Trading Higher Today

    Auris Medical (NASDAQ: EARS) shares are trading higher on Tuesday as traders seem to be mistaking the company for Auris Health, which was acquired by Johnson & Johnson (NYSE: JNJ).Auris Medical is not related to Auris Health.See Also: Johnson & Johnson Sued Over Failing To Deliver Promised Post-Merger Returns To Auris InvestorsAuris Medical Holding Ltd is a clinical-stage biopharmaceutical company. The company develops novel products for the treatment of inner ear disorders. It has two projects ...